Catalog No.
RHC34202
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Alpaca
Isotype
VHH-8His-Cys-tag
Clonality
Monoclonal
Applications
ELISA, FCM
Target
Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Purified by Nickel column.
Accession
P08581
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA1308
Note
For research use only.
Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies., PMID:16095608
Toward chaperone-assisted crystallography: protein engineering enhancement of crystal packing and X-ray phasing capabilities of a camelid single-domain antibody (VHH) scaffold., PMID:18445622
Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy., PMID:22319202
Design and selection of a camelid single-chain antibody yeast two-hybrid library produced de novo for the cap protein of porcine circovirus type 2 (PCV2)., PMID:23469171
Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment., PMID:23952536
Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles., PMID:24139763
In situ proteolysis, crystallization and preliminary X-ray diffraction analysis of a VHH that binds listeria internalin B., PMID:25372824
Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy., PMID:27546726
Structural basis of VHH-mediated neutralization of the food-borne pathogen Listeria monocytogenes., PMID:29976754
Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance., PMID:30361332
VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells., PMID:31544832
Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor., PMID:33418902
Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: A systematic review., PMID:34995616
Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors., PMID:36108560
Biological treatment for erythrodermic psoriasis., PMID:36154361
The Impact of Nanobody Density on the Targeting Efficiency of PEGylated Liposomes., PMID:36499301
Optimizing expression of Nanobody® molecules in Pichia pastoris through co-expression of auxiliary proteins under methanol and methanol-free conditions., PMID:37481525
Bispecific Nanobody-Aptamer Conjugates for Enhanced Cancer Therapy in Solid Tumors., PMID:38225704
Biparatopic Nanobody-Based Immunosorbent for the Highly Selective Elimination of Tumor Necrosis Factor-α., PMID:38364210
Development of an Engineered Single-Domain Antibody for Targeting MET in Non-Small Cell Lung Cancer., PMID:38470611
Nanobody-mediated targeting of zinc phthalocyanine with polymer micelles as nanocarriers., PMID:38492899
Dual-Targeting of the HER2 Cancer Receptor with an Antibody-Directed Enzyme and a Nanobody-Guided MMAE Prodrug Scaffold., PMID:38945824
Autoinhibition of dimeric NINJ1 prevents plasma membrane rupture., PMID:39476863
Evaluation of a Novel MET-Targeting Camelid-Derived Antibody in Head and Neck Cancer., PMID:39513517
Antitumor Activity of a Bispecific Chimera Targeting EGFR and Met in Gefitinib-Resistant Non-Small Cell Lung Cancer., PMID:39586988
Cysteine-selective [188Re]Re(v) radiolabelling of a Nanobody® for targeted radionuclide therapy using a "chelate-then-click" approach., PMID:40078611
Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer., PMID:40136373
For research use only. Not for human or drug use.
